<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03164980</url>
  </required_header>
  <id_info>
    <org_study_id>NOGGO S16/COMPASS</org_study_id>
    <nct_id>NCT03164980</nct_id>
  </id_info>
  <brief_title>Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer</brief_title>
  <acronym>COMPASS</acronym>
  <official_title>Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Eastern Germany Society of Gynaecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>North Eastern Germany Society of Gynaecologic Oncology</source>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, controlled, open-label study including patients with
      recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer.

      The main scope of the trial is to evaluate QoL during chemotherapy comparing trabectedin/PLD
      with other standard platinum-based chemotherapy in platinum-sensitive disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, controlled, open-label study including patients with
      recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer.

      The main scope of the trial is to evaluate QoL during chemotherapy comparing trabectedin/PLD
      with other standard platinum-based chemotherapy in platinum-sensitive disease.

      Patients with recurrent, platinum-sensitive, ovarian, fallopian tube and peritoneal cancer
      will be stratified according to surgery for relapse (R0 vs. R1/2 resection) vs. no surgery in
      the same setting and age (&lt; 75 years vs. ≥ 75 years), and randomized 1:1 to receive either
      trabectedin/PLD (Arm A) or one of 3 platinum-based standard therapies without bevacizumab
      (Arm B, &quot;other standard therapy&quot;). In case of randomization to &quot;other standard therapy&quot;, the
      investigator has the choice between carboplatin/PLD, carboplatin/gemcitabine and
      carboplatin/paclitaxel. Patients in both treatment arms will receive chemotherapy up for 6
      cycles or until disease progression (PD), unacceptable toxicities or patient's wish to stop
      therapy, whichever occurs first.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>observation of change in QoL</measure>
    <time_frame>3 month</time_frame>
    <description>QoL change from baseline (C1 D1) to after 3 months (± 2 week) or at progression, whichever occurs first. (EORTC QLQ-C30 in combination with EORTC QLQ-ov28)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in QoL</measure>
    <time_frame>12 month</time_frame>
    <description>measured at day one of every treatment cycle, at the end of the treatment and after 6 and 12 month (follow up) (EORTC QLQ-C30 in combination with EORTC QLQ-ov28).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>18 month</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Quality of Life</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <description>PLD followed by Trabectedin. Treatment is repeated every 3 weeks for 6 cycles or until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <description>Carboplatin/PLD
Carboplatin/Gemcitabine
Carboplatin/Paclitaxel Patients will be treated for 6 cycles or until PD, unacceptable toxicity or patient's wish to discontinue, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention - observational study</intervention_name>
    <description>To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with histologically confirmed diagnosis of epithelial ovarian cancer, primary
        peritoneal carcinoma or fallopian tube cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women aged ≥ 18 years

          2. Histologically confirmed diagnosis of epithelial ovarian cancer, primary peritoneal
             carcinoma or fallopian tube cancer.

          3. Patients must have platinum-sensitive disease (recurrence ≥ 6 months after end of a
             platinum-based regimen); patients without a platin containing regimen in the previous
             line and recurrence ≥ 6 months are also eligible if fit for platin-containing regime

          4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

          5. Adequate baseline organ function as defined as

               -  Leucocytes &gt; 3.0 x 109/l

               -  Platelet count &gt; 100 x 109/l

               -  Absolute neutrophil count (ANC) ≥1500/mm3

               -  Haemoglobin ≥ 9 g/dl

               -  Alkaline Phosphatase (AP) ≤ 2.5 × ULN (consider hepatic isoenzymes 5 nucleotidase
                  or gamma glutamyl transpeptidase (GGT), if the elevation could be osseous in
                  origin)

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN

               -  Creatinine-Clearance ≥ 60 ml/min (MDRD formula)

               -  Serum creatinine ≤ 1.5 mg/dl

               -  Creatine phosphokinase (CPK) ≤ 2.5 × ULN

               -  Total bilirubin &lt; ULN

          6. Women of childbearing potential should use contraceptives or abstain from heterosexual
             activity for the course of the study through 6 months after the last dose of study
             medication or be surgically sterile.

          7. Adequate cardiac function defined as left ventricular ejection fraction (LVEF) ≥ 50%
             as determined by echocardiogram

          8. Patients must provide written informed consent prior to performance of study specific
             procedures or assessments, and must be willing to comply with treatment and follow up
             assessments and procedures.

        Exclusion Criteria:

          1. Only malignancies, which influence the prognosis

          2. Any unstable or serious concurrent condition (e.g. active infection requiring systemic
             therapy).

          3. Chemotherapy or radiation therapy or tumor embolization within 2 weeks prior to the
             first dose of study drug.

          4. Patients with a recurrence ≤ 6 months after previous therapy

          5. Hypersensitivity to the active substance or to any of the excipients of study drug

          6. Findings from ECG and/or assessment of LVEF which indicate an anthracycline-related
             cardiotoxic process which contradicts administration of liposomal doxorubicin in
             accordance with the requirements of the SmPC of PLD.

          7. Biological therapy, immunotherapy, hormonal therapy or treatment with an
             investigational agent within 14 days (for bevacizumab, 30 days)

          8. Any condition that is unstable or could jeopardize the safety of the patient and their
             compliance in the study

          9. Participation in another clinical study with experimental therapy within the 30 days
             before start of and during treatment

         10. Patients in a closed institution according to an authority or court decision (AMG §
             40, Abs. 1 No. 4)

         11. Patients who are depending on the sponsor/CRO or investigational site as well as on
             the investigator.

         12. Pregnancy or lactation period, or planning to become pregnant within 7 months after
             the end of treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jalid Sehouli, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maren Keller, Dr.</last_name>
    <phone>+49 30 450 564 082</phone>
    <email>m.keller@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gyn-onkologische Schwerpunktpraxis</name>
      <address>
        <city>Berlin</city>
        <zip>10317</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Severin Pergel</last_name>
      <email>severin.pergel@gyn-onko-lichtenberg.de</email>
    </contact>
    <investigator>
      <last_name>Jörg Schilling, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angelika Till, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isil Yalcinkaya</last_name>
      <phone>+(49)30450564404</phone>
      <email>isil.yalcin@charite.de</email>
    </contact>
    <investigator>
      <last_name>Jalid Sehouli, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Radoslav Chekerov, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena-Ioana Braicu, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Krebsheilkunde für Frauen</name>
      <address>
        <city>Berlin</city>
        <zip>13597</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Seher</last_name>
      <email>studien@medionko.de</email>
    </contact>
    <investigator>
      <last_name>Gülten Oskay-Özcelik, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steffen Gläser, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinisches Zentrum Bonn Friedensplatz</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Herz</last_name>
      <email>s.herz@medizinisches-zentrum-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Christian Kurbacher, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jutta Kurbacher</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Studien GbR Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38100</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bibiana Kalensee</last_name>
      <email>kalensee@orenz-hecker-wesche.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Lorenz, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janine Kreiss-Sender, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologisches Zentrum Donauwörth</name>
      <address>
        <city>Donauwörth</city>
        <zip>86609</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Haftmann</last_name>
      <email>onkostudiendon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dirk Hempel, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volker Gressler, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frauenklinik Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Griebsch</last_name>
      <phone>+(49)3514584202</phone>
      <email>Christine.griebsch@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Pauline Wimberger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theresa Link, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Denzel</last_name>
      <email>Katharina.denzel@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Paul Buderath, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pawel March, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Cieslik</last_name>
      <email>caroline.cieslik@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Michaela Bossart, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beate Rautenberg, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis</name>
      <address>
        <city>Fürth</city>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traudl Walter</last_name>
      <email>tgd-studies@hotmail.de</email>
    </contact>
    <investigator>
      <last_name>Harald Wagner, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jochen Wilke, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincentius-Diakonissen-Kliniken g AG</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76135</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lilli Funk</last_name>
      <email>lillli.funk@vincentius-ka.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Tome, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christof Lindner</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZAGO am Helios Klinikum Krefeld</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Songül Uysal</last_name>
      <email>studienabteilung.zago@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gunther Rogmans, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annette Steffen, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iris Eberhardt</last_name>
      <email>iris.eberhardt@edizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Bahriye Aktas, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maren Knödler, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens Einenkel, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik der Otto-von-Guericke-Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39108</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabrina Rudolph</last_name>
      <email>sabrina.rudolph@med.ovgu.de</email>
    </contact>
    <investigator>
      <last_name>Atanas Ignatov, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Holm Eggemann, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Seehase</last_name>
      <email>martina.seehase@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Marco Battista, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annette Hasenburg, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Merkel</last_name>
      <email>jessica.merkel@umm.de</email>
    </contact>
    <investigator>
      <last_name>Michael Bohlmann, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Berlin, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruppiner Kliniken GmbH</name>
      <address>
        <city>Neuruppin</city>
        <zip>16816</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelika Krajewsi</last_name>
      <email>a.krajewski@ruppiner-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Bernd Christensen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvonne Schwarz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caritas Klinikum St. Theresia</name>
      <address>
        <city>Saarbrücken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrike Schilling</last_name>
      <email>u.schilling@caritasklinikum.de</email>
    </contact>
    <investigator>
      <last_name>Mustafa Deryal, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mira Ebner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>amO Wolfsburg</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Liebrich, Dr.</last_name>
      <email>clemens.liebrich@klinikum.wolfsburg.de</email>
    </contact>
    <investigator>
      <last_name>Clemens Liebrich, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Reichl</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of life</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>platinum sensitive</keyword>
  <keyword>recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trabectedin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

